Cumulus Neuroscience, a global digital health company developing multidomain digital biomarkers for the brain, with U.S. offices in Bridgewater, on Wednesday said it appointed Dr. Aman Bhatti as its CEO.
Bhatti, a noted digital health executive with experience launching and scaling world-renowned consumer health care brands, joins Cumulus as it shifts toward health care and expands biopharma partnerships in its next growth phase.
Bhatti’s appointment follows the recent award of a £1.5 million ($1.7 million) U.K. National Institute for Health and Care Research grant to Cumulus and its academic research partners, using the Cumulus platform to improve early dementia diagnosis.
“Neurological disorders are a global health issue, and digital biomarkers — which require integrated, multidomain assessment technologies — are key to supporting faster drug development, disease diagnosis and therapeutic solutions,” Ruth McKernan, co-founder and executive chair, Cumulus, stated.
“Dr. Bhatti’s proven track record of implementing strategies that achieve significant revenue growth in both the biopharma and health care industries, combined with his unique understanding of health care system priorities and patient, physician, biopharma and payer needs, makes him the ideal match to lead Cumulus in its next chapter. With Dr. Bhatti at the helm, Cumulus is poised to accelerate our biopharma and health care commercialization strategies — to help solve the biggest health care challenges in neurodegeneration and psychiatry,” McKernan added.
Brian Murphy, co-founder and chief scientific officer, commented: “Current solutions to measuring brain function don’t satisfy patients, doctors or the scientists who are working to develop new life-changing therapies. Our machine-learning-enabled platform directly measures how a disease affects thinking capability, sleep, mood, language and other aspects of a patient’s daily life. With Aman on-board, the team is excited to bring this easy-to-use solution to bear in global health-care systems.”
Before joining Cumulus, Bhatti was senior vice president of AliveCor BioPharma, where he led a team focused on establishing partnerships with contract research organizations and biopharma companies, drawing upon more than 15 years of experience in prior executive roles at Sanofi, GSK, Novartis and Reckitt.
A pioneer in forging technology-based alliances, he was part of efforts to launch and scale well known global consumer brands such as Mucinex, Theraflu, Flonase, Nicorette and, most recently, KardiaMobile.
